A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy
List of authors.
A list of the investigators in the ENVISION trial is provided in the Supplementary Appendix, available at NEJM.org.
Prepare to become a physician, build your knowledge, lead a health care organization, and advance your career with NEJM Group information and services.
-
NEJM Evidence
NEW! A digital journal for innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making. -
NEJM Catalyst
NEW! Peer-reviewed journal featuring in-depth articles to accelerate the transformation of health care delivery. -
NEJM Journal Watch
Concise summaries and expert physician commentary that busy clinicians need to enhance patient care. -
NEJM Knowledge+
The most effective and engaging way for clinicians to learn, improve their practice, and prepare for board exams. -
NEJM Resident 360
Information, resources, and support needed to approach rotations - and life as a resident. -
NEJM Healer
The most advanced way to teach, practice, and assess clinical reasoning skills. -
NEJM
医学 前 沿
The authorized source of trusted medical research and education for the Chinese-language medical community. -
NEJM Career Center
Valuable tools for building a rewarding career in health care. -
NEJM Library Hub
Information and tools for librarians about site license offerings. -
The New England Journal of Medicine
The most trusted, influential source of new medical knowledge and clinical best practices in the world.
Subscribe to the most trusted
and influential source of
medical knowledge